Current Medical Research and Opinion · 2019 · 24 citations · 13 references
MedicineCardiologyPharmacologyDiabetologyDrug DiscoveryPrecision MedicineCardiovascular PharmacologyDiabetes ManagementDiabetes MellitusDiabetes PharmacotherapyDisease ModelingGlucagon-like Peptide-1 Receptor AgonistsDiabetes-associated Cardiac RiskDipeptidyl PeptidasesGlucagon-like Peptide 1 Receptor AgonismGlucagon-like Peptide 1 SignalingGlucagon-like Peptide-1 Receptor SignalingMachine Learning Prediction ModelsTests Of Proportional Hazards
Machine learning analysis suggested the risk of MI was 37% lower for type 2 diabetes patients without prior MI using GLP-1RAs versus DPP-4is, while the risk was 19% lower for SGLT-2is versus DPP-4is.
13
Dermatologist-level classification of skin cancer with deep neural networks
Andre Esteva, Brett Kuprel, Roberto A. Novoa et al. · Nature · 2017 · 13.8K citations · Full text
International Diabetes Federation 2017
Ann M. Carracher, Payal H. Marathe, Kelly L. Close · Journal of Diabetes · 2018 · 13.6K citations · Full text
Medicine, Endocrinology, Diabetology +11
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman, Christoph Wanner, John M. Lachin et al. · New England Journal of Medicine · 2015 · 12K citations · Full text
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Bruce Neal, Vlado Perkovic, Kenneth W. Mahaffey et al. · New England Journal of Medicine · 2017 · 7.8K citations · Full text